固体脂质纳米颗粒增强德拉曼尼德的莱什曼杀伤性活性
Javier Santamaría-Aguirre1,2,3, Daniela Jacho4, Miguel A Méndez5
1Departamento de Biología Molecular, Universidad de Cantabria, 39011 Santander, Spain.
Pharmaceutics
|January 23, 2024
概括
这项研究将德拉曼胺重新用于固体脂质纳米粒子 (SLNPs),用于治疗莱什曼病. 封装的德拉曼尼德显示出增强的leishmanicidal活性,为这种被忽视的疾病提供了具有成本效益的纳米药物.
科学领域:
- 寄生虫学的寄生虫学
- 纳米医学是一种纳米医学.
- 药物重用 药物重用
背景情况:
- 莱什曼病是一种被忽视的动物性寄生虫病,影响全球数百万人,治疗选择有限,特别是在资源有限的环境中.
- 现有的莱什曼病治疗方法通常是昂贵的,有毒的,或需要专门的管理,阻碍贫困社区的获取.
研究的目的:
- 将已批准的药物转化为负担得起和有效的莱什曼病治疗方法.
- 开发一种新的纳米药物配方,以增强药物输送和对Leishmania寄生虫的疗效.
主要方法:
- 使用数据库审查和分子对接分析对潜在药物候选者的选.
- 在固体脂质纳米颗粒 (SLNPs) 中将选定的药物德拉曼尼德 (delamanid) 纳入.
- 在体外 (细胞体) 和体内评估SLNP有效载荷释放和有效性在受感染的巨细胞和小鼠皮肤模型.
主要成果:
- 德拉曼尼德成功地被封装到SLNP中,证明了巨细胞内和通过表皮的有效有效有效释放.
- 与免费药物相比,封装的德拉曼尼德对Leishmania infantum amastigotes表现出显著更大的leishmanicidal活性.
- 该SLNP配方过程是最小的技术,节能,成本效益,可再生的可扩展的纳米制药生产.
结论:
- 固体脂质纳米颗粒提供了一个有前途的平台,以提高重新定位的药物的疗效,如德拉曼尼德用于莱什曼病治疗.
- 这种方法为被忽视的热带疾病提供了低成本,可访问的纳米药物的潜在途径,改善了治疗的可访问性.
- 开发的SLNP配方支持连贯,低成本的生产,即使在小规模,解决莱什曼病治疗的关键需求.
相关概念视频
01:27Bioavailability Enhancement: Drug Permeability Enhancement
After oral administration, poor permeability often limits the rate at which drugs are absorbed through the intestinal epithelium. Enhancing drug permeability is crucial for effective therapy, and several strategies have been developed to overcome this challenge.One effective strategy involves the use of lipid-based formulations. These formulations enhance dissolution and solubility, targeting physiological mechanisms to increase drug absorption. This includes stimulating bile salt secretion,...
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...